Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docirbrutinib in relapsed/refractory CLL/SLL and NHL
NCT05602363Phase 1Recruiting
- Sponsor
- Carna Biosciences, Inc.
- Start
- Aug 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of docirbrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL) and 4 more (4 arms), sponsored by Carna Biosciences, Inc. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and 1 more. Started Aug 2023; status: recruiting.
02
Drugs
docirbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)Waldenstrom macroglobulinemia (WM)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05602363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602363.